Finch Therapeutics Group, Inc.
FNCH
$13.45
-$0.55-3.93%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 107.00K | 115.00K | 253.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 0.00 | 107.00K | 115.00K | 253.00K |
| Cost of Revenue | 0.00 | 203.00K | 7.20M | 18.75M | 30.61M |
| Gross Profit | 0.00 | -203.00K | -7.09M | -18.64M | -30.36M |
| SG&A Expenses | 19.69M | 22.46M | 26.91M | 31.27M | 37.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.69M | 22.66M | 34.11M | 50.02M | 67.73M |
| Operating Income | -19.69M | -22.66M | -34.00M | -49.90M | -67.47M |
| Income Before Tax | -14.17M | -16.28M | -78.22M | -102.18M | -140.14M |
| Income Tax Expenses | 0.00 | 0.00 | -3.46M | -3.46M | -3.46M |
| Earnings from Continuing Operations | -14.17 | -16.28 | -74.75 | -98.72 | -136.68 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.17M | -16.28M | -74.75M | -98.72M | -136.68M |
| EBIT | -19.69M | -22.66M | -34.00M | -49.90M | -67.47M |
| EBITDA | -19.51M | -22.46M | -32.48M | -47.02M | -63.24M |
| EPS Basic | -8.82 | -10.14 | -46.63 | -61.64 | -85.51 |
| Normalized Basic EPS | -5.59 | -6.40 | -10.77 | -17.22 | -24.58 |
| EPS Diluted | -8.82 | -10.14 | -46.63 | -61.64 | -85.51 |
| Normalized Diluted EPS | -5.59 | -6.40 | -10.77 | -17.22 | -24.58 |
| Average Basic Shares Outstanding | 6.42M | 6.42M | 6.42M | 6.41M | 6.40M |
| Average Diluted Shares Outstanding | 6.42M | 6.42M | 6.42M | 6.41M | 6.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
